A substantial advancement in blood sugar management is emerging with the introduction of tirzepatide at a dosage of 45mg. This innovative formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and offers a potentially greater benefit for individuals with diabetes of type 2. Clinical research have indicated that… Read More